153 results about "Anti-Microbial Agents" patented technology

The present disclosure relates generally to antimicrobial gels. In particular, the present disclosure relates to an antimicrobial gel comprising a eutectic solvent and a gelling agent which can be used as a drug delivery vehicle for antimicrobial agents, including for the topical delivery of antimicrobial agents to the skin of a subject. The present disclosure also relates to processes for preparing the antimicrobial gel, and to methods, uses and compositions comprising the antimicrobial gel.

A comprehensive and sensuous oral cleaner (10A, 10B, 10C, and 10D) is disclosed to automate and modernize all necessary oral hygiene. The cleaner comprises a power driver (12, 12B, 12C, 12D) that can selectively power-drive a replaceable flosser attachment (13, 14, 15, 17), a replaceable synergistic multi-motion toothbrush attachment (29), and an anti-halitosis attachment (81). The driver also power-drives scent from fragrance sources (68, 24) in the attachments for sensuous ambiance while oral cleaning. The toothbrush attachment is detachably connectable to the power driver for imparting plural motions of a long-bristle toothbrush (77). These actions serve for driving long toothbrush bristles to longitudinally penetrate interdentally for power-brushing interdental contours. In the flosser attachment, a floss span is power-driven in plural motions to efficiently remove plaque as the moving span follows, scrubs, and polishes interdental contours between adjacent teeth. Three embodiments of the flosser attachment use warmed power-driven air to dry the used floss for odor-free storage until replacement of the attachment. Alternatively, two of the flosser attachment embodiments feature an antimicrobial (68) that coats the used floss to inhibit microbial activity. The power-driven anti-halitosis attachment drives a multi-bladed tongue scraper (89, 89B) along with pressurized air to neutralize causal anaerobic tongue bacteria.

The invention belongs to the technical field of rubber sealing rings, and particularly discloses a wading rubber sealing ring and a preparation method thereof, the wading rubber sealing ring comprises the following components by weight: 60-70 parts of modified ethylene propylene diene monomer, 35-50 parts of modified white carbon black, 20-30 parts of hydrogenated nitrile rubber, 0-10 parts of fluororubber, 2-5 parts of polyester fiber, 0.5-3 parts of an anti-hydrolysis agent, and 1-3 parts of a hydrophobic agent. 2-4 parts of an antimicrobial agent, 3-5 parts of an anti-aging agent and 1-7 parts of sulfur; the anti-hydrolysis agent is a mixture of tetrakis [beta-(3, 5-di-tert-butyl-4-hydroxyphenyl) propionic acid] pentaerythritol ester and a carbodiimide anti-hydrolysis agent; the hydrophobic agent is a mixture of polydimethylsiloxane and perfluorooctyltriethoxysilane, and the hydrophobic agent is a mixture of polydimethylsiloxane and perfluorooctyltriethoxysilane. The wading rubber sealing rubber ring and the preparation method thereof are suitable for fresh water and warm water scenes, and have wide application prospects in ship sealing and sewage treatment equipment in seawater and industrial wastewater scenes.

The present invention relates to an antimicrobial and healing formulation for skin, designed to effectively target and treat skin conditions such as acne caused by Cutibacterium acnes, cold sore lesions due to the herpes simplex virus, and superficial wounds. This unique formulation combines antimicrobial agents, plant extracts and essential oils in specific proportions in order to exert a synergistic action, enhancing their individual efficacy in the treatment of skin conditions and promoting skin healing. The innovative formulation composed of niaouli (Melaleuca viridiflora) essential oil and tea tree (Melaleuca alternifolia) essential oil, chlorhexidine digluconate, Hamamelis virginiana extract, panthenol, glycerol, and propylene glycol. Each ingredient has been selected for its proven pharmacological properties and its synergistic potential. The formulation works in concert to reduce microbial load, alleviate inflammation, and accelerate skin healing, while providing a gentle and effective application.

The present invention discloses an intelligent, bioengineered wound dressing device that utilizes honey bee-derived therapeutic compounds integrated into a programmable, multi-layered delivery structure designed for sustained antimicrobial release and dynamic wound healing modulation. The device features microencapsulated honey, propolis, and beeswax components embedded within a biocompatible hydrogel matrix, supported by a control technique that processes real-time wound data acquired through embedded biosensors. The technique classifies healing phases, detects wound anomalies, and modulates therapeutic release through actuators based on environmental cues such as pH, temperature, and exudate levels. The system further includes a logic control unit capable of adaptive learning, remote data transmission, and wound trajectory logging, ensuring precise, patient-specific therapeutic delivery. By integrating natural antimicrobial agents with intelligent sensing and release architectures, the invention provides a responsive, self-optimizing wound care platform that enhances healing outcomes, reduces dressing intervention frequency, and improves clinical oversight through real-time therapeutic intelligence.

Novel compositions are described, each comprising at least one active constituent that has a 12-carbon atom backbone as a 12-carbon chain base structure having at least a sub-terminal nitrogen and no terminal amino group. One of the active constituents is Boc-12-Ado-OH (BOA) and / or N,N-dimethyldodecylamine N-oxide (LO). Novel particle or liposomal compositions comprising at least BOA and / or LO may be prepared with an emulsifier and / or lipid and optionally a biopolymer, and may be formulated into pharmaceutically acceptable formulations and / or medicaments with or without one or more pharmaceutically acceptable carriers or excipients for utilization as an antimicrobial against one or more microbial pathogens. The novel antimicrobial compositions have broad-spectrum growth inhibitory or other destructive activity against microbial pathogens, biofilms produced by one or more pathogens, and biofilm infections.

An antimicrobial amphiphilic hydrogel composition for use in haemostasis of a wound comprising: a first cross-linkable amphiphilic component, the first amphiphilic component, in its chemically cross-linked state, being a lyotropic liquid crystal and having an ordered nanostructure of hydrophobic and hydrophilic domains, the hydrogel comprising an antimicrobial agent covalently attached to the hydrophilic and / or hydrophobic domains.

The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and / or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and / or biofilm-embedded microorganisms on a surface.

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The present invention relates to the use of a compound X selected from the group consisting of compounds of formula (I), glyceryl ethers, sorbitan esters and isosorbide esters, as an antimicrobial agent against a microorganism causing dental caries, a microorganism causing dental plaque or a microorganism causing gingivitis, wherein R is selected from saturated hydrocarbon chains having 5 to 23 carbon atoms, unsaturated hydrocarbon chains having 5 to 23 carbon atoms, and mixtures thereof.

Disclosed herein are compositions for topical treatment that can include a therapeutic agent (preferably a topical antimicrobial or antifungal agent such as efinaconazole, tavaborole, or ciclopirox), a non-volatile organic solvent (preferably natural or synthetic vitamin E or vitamin E acetate), and optionally an emollient (such as cholesterol). Also disclosed herein are methods of treating diseases or disorders (preferably as a disease or disorder of the nail, nail bed, or skin, such as onychomychosis) by topically administering compositions that can include a therapeutic agent, a non-volatile organic solvent, and optionally an emollient.

Disclosed are adhesive medical films incorporating one or more cationic steroidal antimicrobial (CSA) compounds. The adhesive medical film is in the form of a tape, dressing, or sheet, configured for contact against dermal tissue to provide securement of medical devices, wound care, wound closure, and / or scar prevention. The adhesive medical film includes (i) a polymer adhesive (e.g., pressure-sensitive adhesive) in which one or more CSA compounds are distributed, and (ii) optionally, a backing substrate upon which the polymer adhesive is disposed. Examples of polymer adhesives include polyacrylate and silicone adhesives. The adhesive medical films, when used, reduce microbial colonization and / or growth, both on the films during storage and at a dermal site, as compared to the same adhesive medical film without incorporated CSA compounds.

The present invention is directed to a surfactant preparation and end use product comprising alcohol alkoxy sulfates where the preparation and composition display mitigation in dioxane formation when antimicrobial agent is present in the surfactant preparation and end use product.

A method for preserving a tissue graft includes submerging the tissue graft in a solution containing one or more antimicrobial and / or stabilizing agents and storing the tissue graft in the solution for a period of time of at least 24 hours while the solution is in an unfrozen state. A tissue preservation system includes a solution containing one or more antimicrobial and / or stabilizing agents and a tissue graft in the solution.

This invention provides an antibacterial and antiviral fabric comprising a fabric substrate and an antimicrobial coating. The antimicrobial coating formed on the fabric substrate has an antimicrobial agent embedded or surface-adhered in a three-dimensional porous network of nano-binder particles. The three-dimensional porous network is formed by interconnecting the nano-binder particles through van der Waals forces or Coulomb forces. The antibacterial and antiviral fabric has at least 99% antibacterial efficacy while retaining physical properties comparable to uncoated fabric. This invention also provides an antibacterial and antiviral formulation and a method for preparing antibacterial and antiviral nanoparticles.

Embodiments of a tourniquet are provided. The tourniquet comprises an elastic layer, an adhesive layer on a first side of the elastic layer and a release layer on a second, opposite side of the elastic layer. In some embodiments, the adhesive layer comprises an antimicrobial agent incorporated into an acrylic adhesive that does not interfere with the function of adhesively securing layers of the tourniquet under tension to their underlying layers. This arrangement is highly beneficial, as the antimicrobial present in the acrylic adhesive portion of the tourniquet will be placed in contact with any underlying wounds, thereby reducing the risk of infection for traumatic injury victims.

The present invention relates to pyridine-2-thiol 1-oxide derivatives and their use as antimicrobial agents in infectious diseases of mammals (humans and animals) caused by fungi or bacteria, in particular belonging to the Mycobacteriaceae family, especially diseases caused by Mycobacterium abscessus or Mycobacterium tuberculosis.

The present invention relates to two-component composition for preparing polyurethane,PU foam wound dressing, said composition comprising a first polyol-based mixture component comprising a polyether polyol comprising high-reactivity-capped polyether triol, water, a tertiary amine catalyst in a solution of dipropylene glycol, an emulsifier and pH buffer, a curing agent with a bi-functional organic compound, a foaming agent, a delayed-action blowing catalyst, and a silicone co-surfactant, and copper and chitosan and a second prepolymer based component comprising diphenyl methane diisocyanate,MDI-based prepolymers, characterized in that, said PU foam wound dressing is infused with copper and chitosan as antimicrobial agents.

The present invention includes methods of using improved compositions and improved compositions comprising thermally stable plant juice soluble vegetable proteins for resisting pathogenic effects; the improvements include that the composition comprising heat stable plant juice soluble vegetable proteins is essentially a water insoluble concentrated substance free of components that are more soluble in plant juice, and is enriched in heat stable proteins of plant juice; dosage forms prepared from the composition are useful for adiponectin agonist action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity, and are useful for antimicrobial action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity. The present invention relates to antimicrobial agents for reducing the risk of or treating microbial infections in plants and animals with or without synergy with other antimicrobial agents. The present invention includes a composition substantially characterized by the infrared absorption spectrum provided in the present invention.

The invention provides a disulfide compound of formula (I) as defined in the claims for use as a medicament, including its use as an antimicrobial agent, such as an antibacterial agent; and its use in the treatment of cancer. The invention also provides a pharmaceutical composition per se comprising a disulfide compound of formula (I) and one or more other antibiotics, in particular aminoglycoside antibiotics, including the compound fradiomycin, as well as the use of said pharmaceutical composition as a medicament, including its use as an antimicrobial agent.

A catheter cap (100) includes a housing defining at least one cavity (104) and an opening (106) at a distal end of the housing, and an antimicrobial agent (108) within the at least one cavity. The housing is configured to couple to a catheter luer (22) at the distal end. The at least one cavity is configured to contain a catheter lock solution in contact with the catheter luer at the opening. The antimicrobial agent is present in an amount sufficient to maintain a minimum inhibitory concentration (MIC) of the antimicrobial agent in the catheter lock solution for a period of time between successive operations of the catheter luer.

The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.

The present invention discloses an ophthalmic composition comprising dexamethasone or its pharmaceutically acceptable salt thereof and that is used to treat cataract surgery pain and diabetic macular edema. The present invention relates to use of a topically administrate ophthalmic suspension composition of dexamethasone, or it pharmaceutically acceptable salt thereof suspended in pharmaceutically acceptable vehicle, wherein the pharmaceutical acceptable vehicle comprises at least one excipient selected from suspending agent, tonicity agent, antimicrobial agent, buffering agent, chelating agent, antioxidant, surface active agent, and pH adjusting agent.

The present invention relates to an adhesive oral film strip designed for the controlled release of sodium fluoride and other therapeutic agents to enhance oral health. The strip comprises a polymeric matrix — primarily polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), and carboxymethylcellulose (CMC) which provides mechanical integrity, controlled erosion, and sustained release of active ingredients when applied to the teeth. The invention addresses the challenges of traditional fluoride delivery methods by enabling targeted, prolonged, and customizable administration of fluoride and additional agents such as remineralization compounds, desensitizers, antimicrobials, and whitening agents. The strip may feature multilayer constructions, heterogeneous therapeutic agent distribution, and auxiliary components for improved adhesion, user compliance, and safety. The invention further encompasses methods of manufacture, application, and integration into comprehensive dental care kits, offering solutions for diverse populations and oral health needs. This innovation provides a significant advancement in preventive dentistry by improving caries prevention, enamel remineralization, and overall oral hygiene, while minimizing risks such as fluorosis and enhancing user experience.

Pre-dosed wipes and packaged systems of such wipes including a nonwoven substrate formed from renewable natural plant-based fibers or derivatives of such fibers. The pre-dosed wipe as a whole meets applicable biodegradability / compostability standards (e.g., ASTM D6400, EN13432 or the like). The wipe may be a sanitizing or disinfecting wipe, including a quaternary ammonium compound as an antimicrobial agent in the composition with which the substrate is dosed. The composition may also include water and a surfactant. The wipe may be substantially void of thermoplastic fibers, such as PE, PP, PET, as well as so-called biodegradable polyesters and the like (e.g., PHA, PLA, PVOH). The nonwoven substrate may be formed by any of various techniques, an example of which is spunlace. The formulation may have a pH of at least 5 (e.g., 6 to 8), to maintain tensile strength of the natural plant-based substrate.

A composition comprising a solubiliser, at least one preservative, at least one liquid emollient and at least one antimicrobial agent, wherein the composition comprises thymol and carvacrol. The antimicrobial agent may comprise essential oils, active ingredients derived from essential oils or synthetic equivalents thereof and, optionally, additional antimicrobial compounds. The composition may comprise thymol, carvacrol, levulinic acid and lauric acid. The composition may be used for intra-anal douching and may be used to reduce the risk of the transmission of sexually transmitted diseases (STDs) and / or sexually transmitted infections (STIs). The composition may be essentially free of water and may be provided as a single unit dosage formulation. Alternatively, the composition may further comprise water and may be provided as a single unit dosage or multi-dosage formulation. Methods of making the composition that is essentially free of water and the composition further comprising water are also disclosed.

The present disclosure relates to bandages used to protect and disinfect or provide a protective antimicrobial barrier to a surgical site with one or more percutaneous pins or wires extending therefrom. The bandage includes an antimicrobial agent, an absorbent layer, an adhesive layer, and one or more slits designed to receive therethrough a percutaneous pin or wire extending from the surgical site. The bandage enhances and facilitates the ease of protecting a surgical site with one or more percutaneous pins or wires extending therefrom without disturbing the pins or wires and while protecting the surgical site from infection, contamination, and injury during the healing process.

The present invention discloses cationic guanidine based peptides, oligomers, and oligomer-peptide hybrid compounds, and also envisages within its scope monomers for obtaining peptides, oligomers and oligomer-peptide hybrid compounds, and the processes thereof. The present invention additionally relates to the composition for administration of the compounds and their utility as antimicrobial, antifungal agent and as a carrier therapeutic molecules for drug delivery applications.

A container for storing diaphragm mouth calls may include a body having an internal cavity configured to enclose one or more diaphragm mouth calls. A moisture control system may be integrated within the body, the moisture control system may comprise a moisture-retaining component and a plurality of adjustable airflow vents. A magnetic securing system may be within the body, the magnetic securing system may comprise a magnetic plate configured to secure the diaphragm mouth calls in position. The moisture-retaining component may comprise a replaceable moisture pad impregnated with antimicrobial agents to prevent growth of mold and bacteria. The magnetic plate may comprise multiple magnetic zones of varying magnetic strengths, configured to accommodate diaphragm mouth calls of different sizes and weights. The adjustable airflow vents may be operable from the exterior of the container and may include filters to prevent ingress of dust and particulate matter.

A pre-saturated wipe product is disclosed that is well suited for destroying non-enveloped viruses, including norovirus. The wipe composition includes a first antimicrobial agent blended with a second agent, such as a preservative. The wipe product can destroy and kill non-enveloped viruses completely in a relatively short contact time, even at very low concentrations in the wipe composition.